So Alan, Rocchi Palma, Gleave Martin
The Prostate Centre at Vancouver General Hospital, University of British Columbia, Canada.
Curr Opin Urol. 2005 Sep;15(5):320-7. doi: 10.1097/01.mou.0000175572.46986.2c.
In this paper, we will review the recent advances in antisense oligonucleotide therapy in the treatment of superficial bladder cancer. Bladder cancer has an exciting potential as a model to study antisense oligonucleotide therapy because of the ease of accessibility of treatment, ease of diagnosis through biopsy and urine cytology, and direct observation of treatment efficacy through cystoscopy and posttreatment biopsy.
We will elaborate on the recent developments in the delivery of antisense oligonucleotide and the implications of these results on the use of antisense oligonucleotide intravesically. We will also discuss recent preclinical in-vitro results of antisense oligonucleotide therapy in different bladder cancer cell lines.
Recent developments of the in-vitro and animal in-vivo effectiveness of antisense treatment in bladder cancer provide the foundation to pursue future phase I clinical trials. Antisense oligonucleotide technology is a promising tool that may become an effective method of treating bladder cancer.
在本文中，我们将回顾反义寡核苷酸疗法在浅表性膀胱癌治疗中的最新进展。膀胱癌作为研究反义寡核苷酸疗法的模型具有令人兴奋的潜力，这是因为其治疗易于实施，可通过活检和尿液细胞学检查轻松诊断，并且能够通过膀胱镜检查和治疗后活检直接观察治疗效果。
我们将详细阐述反义寡核苷酸递送方面的最新进展以及这些结果对膀胱内使用反义寡核苷酸的意义。我们还将讨论反义寡核苷酸疗法在不同膀胱癌细胞系中的近期临床前体外研究结果。
反义疗法在膀胱癌体外和动物体内有效性的最新进展为开展未来的I期临床试验奠定了基础。反义寡核苷酸技术是一种有前景的工具，可能成为治疗膀胱癌的有效方法。
